SYBX vs. EGRX, BYSI, SPRO, OVID, CNTB, GNLX, EYEN, THTX, EPRX, and VTVT
Should you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Eagle Pharmaceuticals (EGRX), BeyondSpring (BYSI), Spero Therapeutics (SPRO), Ovid Therapeutics (OVID), Connect Biopharma (CNTB), Genelux (GNLX), Eyenovia (EYEN), Theratechnologies (THTX), Eupraxia Pharmaceuticals (EPRX), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical preparations" industry.
Eagle Pharmaceuticals (NASDAQ:EGRX) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
Eagle Pharmaceuticals received 81 more outperform votes than Synlogic when rated by MarketBeat users. Likewise, 69.59% of users gave Eagle Pharmaceuticals an outperform vote while only 69.54% of users gave Synlogic an outperform vote.
Eagle Pharmaceuticals currently has a consensus price target of $17.00, indicating a potential upside of 197.20%. Synlogic has a consensus price target of $65.00, indicating a potential upside of 3,792.22%. Given Eagle Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Synlogic is more favorable than Eagle Pharmaceuticals.
Eagle Pharmaceuticals has a net margin of 0.00% compared to Eagle Pharmaceuticals' net margin of -2,284.65%. Synlogic's return on equity of 0.00% beat Eagle Pharmaceuticals' return on equity.
In the previous week, Synlogic had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 4 mentions for Synlogic and 3 mentions for Eagle Pharmaceuticals. Synlogic's average media sentiment score of 0.96 beat Eagle Pharmaceuticals' score of 0.22 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.
Eagle Pharmaceuticals has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eagle Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 8.0% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Eagle Pharmaceuticals beats Synlogic on 12 of the 18 factors compared between the two stocks.
Get Synlogic News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synlogic Competitors List
Related Companies and Tools
Free SYBX Stock Alerts